What is Renovacor Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Renovacor's cash to debt ratio for the quarter that ended in Sep. 2022 was 35.22.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Renovacor could pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Renovacor's Cash-to-Debt or its related term are showing as below:
RCOR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 35.22 Med: No Debt Max: No Debt
Current: 35.22
During the past 2 years, Renovacor's highest Cash to Debt Ratio was No Debt. The lowest was 35.22. And the median was No Debt.
Renovacor Cash-to-Debt Historical Data
The historical data trend for Renovacor's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Renovacor Cash-to-Debt Chart
|
Renovacor Annual Data
|
|
Trend |
Dec20 |
Dec21 |
| Cash-to-Debt |
|
No Debt |
No Debt |
|
Renovacor Quarterly Data
|
|
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
No Debt |
No Debt |
No Debt |
109.72 |
35.22 |
Competitive Comparison of Renovacor's Cash-to-Debt
For the Biotechnology subindustry, Renovacor's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renovacor's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Renovacor's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Renovacor's Cash-to-Debt falls into.
Renovacor Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Renovacor's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
Renovacor had no debt (1).
Renovacor's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renovacor (Renovacor) Business Description
Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
| Joseph S Carroll |
officer: Chief Accounting Officer |
C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
| Gregory F Covino |
director |
C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477 |
| Joan Lau |
director |
C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
| Benz Edward J. Jr |
director |
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
| Needham Thomas E. Jr. |
director |
MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
| Frederick W Driscoll |
officer: Chief Financial Officer |
|
| Jonas Grossman |
director |
17 STREET, SUITE 1600, NEW YORK NY 10004 |
| Gbolahan Amusa |
director |
17 STATE STREET 21 FLOOR, NEW YORK NY 10004 |
| Magdalene Cook |
director, officer: Chief Executive Officer |
C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
| Matthew Killeen |
officer: Chief Scientific Officer |
C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
| Rtw Investments, Lp |
10 percent owner |
40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
| Rtw Master Fund, Ltd. |
10 percent owner |
C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008 |
| Roderick Wong |
10 percent owner |
C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
| Marc Semigran |
officer: Chief Medical Officer |
C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
| Wendy F Dicicco |
officer: Interim CFO |
|
Renovacor (Renovacor) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCOR has been successfully added to your